亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparative Effectiveness of Brivaracetam, Cenobamate, Lacosamide, and Perampanel in Focal Epilepsy

吡仑帕奈 医学 癫痫 儿科 内科学 梅德林 重症监护医学 麻醉 中枢神经系统疾病 癫痫综合征
作者
Emanuele Cerulli Irelli,Roberta Roberti,Maria Sole Borioni,Francesca Anzellotti,Vincenzo Belcastro,Simone Beretta,Giovanni Boero,Paolo Bonanni,Valentina Chiesa,Alfredo D’Aniello,Filippo Dainese,Francesco Deleo,Giovanni De Maria,Giancarlo Di Gennaro,Gianfranco Di Gennaro,Giuseppe Didato,Fedele Dono,Giovanni Falcicchio,Edoardo Ferlazzo,Francesco Fortunato
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:83 (4): 320-320 被引量:16
标识
DOI:10.1001/jamaneurol.2025.5625
摘要

Importance: Treatment decisions in drug-resistant focal epilepsy remain largely empirical, as direct comparative evidence among newer antiseizure medications (ASMs) is limited. Real-world data can complement randomized clinical trials by providing insights into long-term effectiveness and safety across diverse populations. Objective: To compare effectiveness and safety of brivaracetam, cenobamate, lacosamide, and perampanel as adjunctive therapies in adults with drug-resistant focal epilepsy. Design, Setting, and Participants: This was a multicenter pooled analysis of 4 previously conducted retrospective real-world medical record-review studies (January 2017-January 2024). Included were adult patients (aged ≥16 years) with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy. Participants were recruited from 71 epilepsy centers. Exposures: Add-on treatment with brivaracetam, cenobamate, lacosamide, or perampanel. Main Outcomes and Measures: The primary outcome was the responder rate at 6 months, defined as greater than or equal to 50% seizure frequency reduction from baseline. Secondary outcomes included 12-month responder rate, seizure freedom (≥3 months at 6 months and ≥6 months at 12 months), and 12-month ASM retention. Safety was assessed by incidence of adverse effects. Generalized linear mixed models adjusted for demographic and clinical covariates were used to compare treatment outcomes, with cenobamate as reference ASM. Results: Of 2386 ASM prescriptions screened, 1993 prescriptions from 1949 patients (1036 of 1947 female [53.2%]; sex information was missing in 0.1% of prescriptions) with a median (IQR) age of 42 (29-55) years at ASM prescription, met inclusion criteria and were included in the pooled analysis. Brivaracetam accounted for 953 prescriptions (47.8%), followed by perampanel (607 [30.5%]), lacosamide (241 [12.1%]), and cenobamate (192 [9.6%]). After adjustment, cenobamate demonstrated significantly higher odds of 50% or greater response at 6 months compared with brivaracetam (odds ratio [OR], 0.18; 95% CI, 0.12-0.28; P < .001), perampanel (OR, 0.26; 95% CI, 0.16-0.42; P < .001), and lacosamide (OR, 0.29; 95% CI, 0.17-0.49; P < .001). Results were consistent for secondary effectiveness outcomes at 12 months, with cenobamate outperforming other ASMs in terms of 50% or greater response and seizure freedom. Cenobamate was associated with the highest rate of adverse effects during follow-up (111 [57.8%]), and lacosamide was associated with the lowest (35 [14.8%]). Cenobamate was associated with a higher likelihood of treatment retention at 12 months compared with brivaracetam (OR, 0.43; 95% CI, 0.26-0.69; P < .001) and perampanel (OR, 0.56; 95% CI, 0.32-0.99; P = .047), with no significant difference vs lacosamide (OR, 0.81; 95% CI, 0.41-1.59; P = .53). Conclusions and Relevance: These study findings suggest superior effectiveness of cenobamate over brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy in a large real-world setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
涂豆泥发布了新的文献求助30
3秒前
4秒前
2589发布了新的文献求助10
10秒前
老孟完成签到,获得积分10
11秒前
14秒前
大方大船完成签到,获得积分10
19秒前
22秒前
27秒前
Maestro_S的应助被科研通管家采纳,获得10
28秒前
28秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
28秒前
30秒前
缓慢芷文完成签到,获得积分10
31秒前
GXY完成签到,获得积分10
31秒前
msezhj完成签到 ,获得积分10
34秒前
111完成签到,获得积分10
35秒前
35秒前
IGNIS完成签到 ,获得积分10
35秒前
龙龙发布了新的文献求助10
37秒前
38秒前
FashionBoy的应助被2589采纳,获得20
43秒前
龙龙完成签到,获得积分10
49秒前
平淡的友儿完成签到 ,获得积分10
51秒前
浮云发布了新的文献求助20
51秒前
坦率寻菡完成签到,获得积分10
55秒前
55秒前
直率的宛丝完成签到,获得积分10
59秒前
1分钟前
1分钟前
待续完成签到 ,获得积分10
1分钟前
Louislee发布了新的文献求助10
1分钟前
勤劳的夏天完成签到,获得积分10
1分钟前
sufasci发布了新的文献求助10
1分钟前
小羊完成签到 ,获得积分10
1分钟前
1分钟前
在喝咖啡ing完成签到,获得积分10
1分钟前
共享精神的应助被稳重又琴采纳,获得60
1分钟前
万能图书馆的应助被Louislee采纳,获得10
1分钟前
1分钟前
sjn完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780029
捐赠科研通 7764837
什么是DOI,文献DOI怎么找? 3431499
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476579